Rapid access mechanisms for new medicines

The UK is piloting rapid access routes for new medicines

The United Kingdom, in partnership with the pharmaceutical industry, is launching a series of pilot schemes aimed at helping patients gain faster access to new medicines.

These initiatives have been developed as part of the implementation of the UK–US pharmaceutical trade deal. They were prepared by a joint government and industry taskforce with input from patient advocacy groups and are designed to test new approaches to medicines pricing, access, and adoption.

According to preliminary estimates, if implemented successfully, the pilots could enable up to five new medicines to be approved for use by the NHS each year.

One of the pilot schemes will focus on how innovative treatments that have already met safety, quality, and clinical standards, including therapies for rare diseases, can be provided more quickly to eligible NHS patients.

Other areas will explore ways to account for the wider economic and social benefits of new medicines, such as enabling patients to return to work after treatment, improving access to priority medicines through regional funding, and involving industry co-investment in screening, testing, and the full patient care journey.

Industry representatives note that these measures may become an important step toward faster and fairer patient access to innovative treatments, while also ensuring effective use of healthcare resources.

At the same time, the UK–US pharmaceutical agreement and related pilot schemes have received mixed reactions. Some analyses suggest that such measures could significantly increase NHS costs. The UK Department of Health and Social Care, however, states that the pilots support the government’s commitment to increase spending on innovative medicines and deliver faster, fairer, and more equitable NHS patient access to cutting-edge therapies.